Distinguished in Prostate Cancer

Javier M. Puente

Madrid, MD, ES 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Prostate Cancer
Madrid, MD, ES 
OverviewLocationsClinical Research

Overview

Javier Puente practices in Madrid, Spain. Mr. Puente is rated as a Distinguished expert by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Urothelial Cancer, Prostate Cancer, Renal Cell Carcinoma (RCC), Cystectomy, and Nephrectomy.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 18 articles and participated in 3 clinical trials in the study of Prostate Cancer.

Gender
Male

Locations

Madrid, MD, Spain
Other Locations
Barcelona, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

International Registry for Men With Advanced Prostate Cancer (IRONMAN)
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Other
Observational Retrospective-prospective Study in Patients With Genitourinary Tumors Presenting COVID-19 Infection (SOGUG-COVID-19)
Observational Retrospective-prospective Study in Patients With Genitourinary Tumors Presenting COVID-19 Infection (SOGUG-COVID-19)
Enrollment Status: Completed
Publish Date: April 01, 2025
A Phase I-II Study to Evaluate the Efficacy and Safety of Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer After Failure to First-line Platinum-based Chemotherapy
A Phase I-II Study to Evaluate the Efficacy and Safety of Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer After Failure to First-line Platinum-based Chemotherapy
Enrollment Status: Completed
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drugs: Niraparib, Cabozantinib
Study Phase: Phase 1/Phase 2
Phase II Multicentre, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Avelumab With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone in Patients With Unresectable or Metastatic Urothelial Carcinoma (UC) Who Have Not Received Prior Systemic Therapy and Who Are Ineligible to Receive Cisplatin-based Therapy.
Phase II Multicentre, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Avelumab With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone in Patients With Unresectable or Metastatic Urothelial Carcinoma (UC) Who Have Not Received Prior Systemic Therapy and Who Are Ineligible to Receive Cisplatin-based Therapy.
Enrollment Status: Completed
Publish Date: October 18, 2023
Intervention Type: Combination product
Study Drugs: Avelumab 10mg/kg with Carboplatin/Gemcitabine, Carboplatin/Gemcitabine Alone
Study Phase: Phase 2
A Multi-arm, Multi-stage, Randomized Phase II/III Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
A Multi-arm, Multi-stage, Randomized Phase II/III Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Enrollment Status: Unknown
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Docetaxel, ADT
Study Phase: Phase 2/Phase 3
View 4 Less Clinical Trials

94 Total Publications

Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial.
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Puente's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile